Feng Yao-Xu, Su Li-Ping
Graduate School of Shanxi Medical University,Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.
Department of Hematology, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030000, Shanxi Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Feb;29(1):98-103. doi: 10.19746/j.cnki.issn.1009-2137.2021.01.016.
To evaluate the prognostic value of GELTAMO-IPI for patients with diffuse large B-cell lymphoma (DLBCL).
The clinical data of 238 newly diagnosed DLBCL patients treated in Shanxi Cancer Hospital from September 2011 to March 2016 were collected retrospectively, the risk stratification and prognostic evaluation of the patients were analyzed according to GELTAMO-IPI. Progression-free survival (PFS) and overall survival (OS) of the patients were analyzed by the Kaplan-Meier method, COX regression analysis was used to compare the risk of death and progress in each risk group. Harrell's C statistics was used to compare the prognostic stratification ability of each model.
The 3-year OS rate statistics showed that both IPI and GELTAMO-IPI could distinguish low risk group and Low-intermediate risk group, but the prognosis stratification ability of IPI was better (IPI: HR=5.085, P<0.05; GELTAMO-IPI; HR=4.639, P>0.05). GELTAMO-IPI could distinguish High-intermediate risk group from high risk group (GELTAMO-IPI: HR=2.966, P<0.05; 3 years OS rate was 34.5%), but the ability of IPI to identify high risk groups was weak (3 years OS>50%). The results of Harrell's C statistics showed the C-index of IPI and GELTAMO-IPI was 0.687 and 0.721 (P<0.001); the C-index of the predicted PFS was 0.672 and 0.700 (P<0.001). It was suggested that the prognostic stratification ability of GELTAM0-IPI be superior to that of IPI, R-IPI, NCCN-IPI.
GELTAMO-IPI can make a clear distinction between DLBCL patients with different prognosis, especially for high-risk patients, and the prognostic stratification ability of GELTAMO-IPI is significantly better than that of IPI.
评估GELTAMO-IPI对弥漫性大B细胞淋巴瘤（DLBCL）患者的预后价值。
回顾性收集2011年9月至2016年3月在山西省肿瘤医院治疗的238例新诊断DLBCL患者的临床资料，根据GELTAMO-IPI对患者进行风险分层和预后评估。采用Kaplan-Meier法分析患者的无进展生存期（PFS）和总生存期（OS），采用COX回归分析比较各风险组的死亡和进展风险。使用Harrell's C统计量比较各模型的预后分层能力。
3年总生存率统计显示，IPI和GELTAMO-IPI均能区分低风险组和低中风险组，但IPI的预后分层能力更好（IPI：HR=5.085，P<0.05；GELTAMO-IPI：HR=4.639，P>0.05）。GELTAMO-IPI能区分高中风险组和高风险组（GELTAMO-IPI：HR=2.966，P<0.05；3年总生存率为34.5%），但IPI识别高风险组的能力较弱（3年总生存率>50%）。Harrell's C统计量结果显示，IPI和GELTAMO-IPI的C指数分别为0.687和0.721（P<0.001）；预测PFS的C指数分别为0.672和0.700（P<0.001）。提示GELTAM0-IPI的预后分层能力优于IPI、R-IPI、NCCN-IPI。
GELTAMO-IPI能明确区分不同预后的DLBCL患者，尤其是高危患者，且GELTAMO-IPI的预后分层能力明显优于IPI。
